Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles

.

Source: Expert Opinion on Drug Delivery - February 22, 2020 Category: Drugs & Pharmacology Authors: Binquan Wu Amin Li Yinci Zhang Xueke Liu Shuping Zhou Huaiyong Gan Shiyu Cai Yong Liang Xiaolong Tang Source Type: research